1. Date of download: 7/7/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Antiarrhythmic Drugs for Maintaining Sinus Rhythm After Cardioversion of Atrial Fibrillation: A Systematic Review of Randomized Controlled Trials Arch Intern Med. 2006;166(7):719-728. doi:10.1001/archinte.166.7.719 Selection of studies for inclusion. Figure Legend:

2. Date of download: 7/7/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Antiarrhythmic Drugs for Maintaining Sinus Rhythm After Cardioversion of Atrial Fibrillation: A Systematic Review of Randomized Controlled Trials Arch Intern Med. 2006;166(7):719-728. doi:10.1001/archinte.166.7.719 Funnel plot based on results for mortality. OR indicates odds ratio; SE, standard error. Figure Legend:

3. Date of download: 7/7/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Antiarrhythmic Drugs for Maintaining Sinus Rhythm After Cardioversion of Atrial Fibrillation: A Systematic Review of Randomized Controlled Trials Arch Intern Med. 2006;166(7):719-728. doi:10.1001/archinte.166.7.719 Overall mortality. Some studies compared more than 2 drugs, so the total numbers of studies and patients in the figure are greater than the absolute numbers of studies and patients included. CI indicates confidence interval; NA, not applicable; and OR, odds ratio. Boldface values are significant. Figure Legend:

4. Date of download: 7/7/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Antiarrhythmic Drugs for Maintaining Sinus Rhythm After Cardioversion of Atrial Fibrillation: A Systematic Review of Randomized Controlled Trials Arch Intern Med. 2006;166(7):719-728. doi:10.1001/archinte.166.7.719 Withdrawals due to adverse effects and proarrhythmia. Some studies compared more than 2 drugs, so the total numbers of studies and patients in the table are greater than the absolute numbers of studies and patients included. When the numbers of studies pooled were different for the 2 outcomes, the number combined to evaluate withdrawals is given first, followed by the number combined to evaluate proarrhythmia. CI indicates confidence interval; OR, odds ratio; PAFAC, Prevention of Atrial Fibrillation After Cardioversion; SOPAT, Suppression of Paroxysmal Atrial Tachyarrhythmias; asterisk, PAFAC and SOPAT trials in both cases, which showed heterogeneity compared with other studies on quinidine or on sotalol; and dagger, the OR was calculated by the random- effects model, because the test for heterogeneity between pooled studies was significant. Figure Legend:

5. Date of download: 7/7/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Antiarrhythmic Drugs for Maintaining Sinus Rhythm After Cardioversion of Atrial Fibrillation: A Systematic Review of Randomized Controlled Trials Arch Intern Med. 2006;166(7):719-728. doi:10.1001/archinte.166.7.719 Withdrawals due to adverse effects. Some studies compared more than 2 drugs, so the total numbers of studies and patients shown are greater than the absolute numbers of studies and patients included. CI indicates confidence interval; OR, odds ratio; PAFAC, Prevention of Atrial Fibrillation After Cardioversion study; and SOPAT, Suppression of Paroxysmal Atrial Tachyarrhythmias. Comparisons marked with an asterisk were from the PAFAC and SOPAT trials in both cases, which showed heterogeneity compared with other studies of quinidine or sotalol. Dagger indicates that OR was calculated by random effects model because the test for heterogeneity between pooled studies was significant for those comparisons. Boldface P values are significant. Figure Legend:

6. Date of download: 7/7/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Antiarrhythmic Drugs for Maintaining Sinus Rhythm After Cardioversion of Atrial Fibrillation: A Systematic Review of Randomized Controlled Trials Arch Intern Med. 2006;166(7):719-728. doi:10.1001/archinte.166.7.719 Proarrhythmia (either bradycardia or tachycardia). Some studies compared more than 2 drugs, so the total numbers of studies and patients shown are greater than the absolute numbers of studies and patients included. CI indicates confidence interval; NA, not applicable; OR, odds ratio. Boldface P values are significant. Figure Legend:

7. Date of download: 7/7/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Antiarrhythmic Drugs for Maintaining Sinus Rhythm After Cardioversion of Atrial Fibrillation: A Systematic Review of Randomized Controlled Trials Arch Intern Med. 2006;166(7):719-728. doi:10.1001/archinte.166.7.719 Atrial fibrillation recurrence. Some studies compared more than 2 drugs, so the total numbers of studies and patients in the figure are greater than the absolute numbers of studies and patients included. CI indicates confidence interval; OR, odds ratio. Figure Legend: